NO20080869L - For tidlig egglosningspreventivt middel - Google Patents

For tidlig egglosningspreventivt middel

Info

Publication number
NO20080869L
NO20080869L NO20080869A NO20080869A NO20080869L NO 20080869 L NO20080869 L NO 20080869L NO 20080869 A NO20080869 A NO 20080869A NO 20080869 A NO20080869 A NO 20080869A NO 20080869 L NO20080869 L NO 20080869L
Authority
NO
Norway
Prior art keywords
preventive
premature ovulation
vitro fertilization
ovulation
premature
Prior art date
Application number
NO20080869A
Other languages
English (en)
Other versions
NO339063B1 (no
Inventor
Masami Kusaka
Shuichi Furuya
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20080869L publication Critical patent/NO20080869L/no
Publication of NO339063B1 publication Critical patent/NO339063B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Preventivt middel for prematur ovulering som kan inntre under in vitro-fertilisering eller embryotransplantasjon. Middelet omfatter en ikke-peptidisk forbindelse med en antagonistisk effekt på et gonadotropinfrigivende hormon. Det preventive middel viser lav toksisitet, kan administreres oralt og har utmerket preventiv effekt på preventiv ovulering under in vitro-fertilisering eller embryotransplantasjon.
NO20080869A 2005-07-22 2008-02-18 Middel for inhibering av prematur ovulering NO339063B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005212973 2005-07-22
PCT/JP2006/314943 WO2007011072A1 (ja) 2005-07-22 2006-07-21 早発排卵の防止剤

Publications (2)

Publication Number Publication Date
NO20080869L true NO20080869L (no) 2008-04-10
NO339063B1 NO339063B1 (no) 2016-11-07

Family

ID=37668939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080869A NO339063B1 (no) 2005-07-22 2008-02-18 Middel for inhibering av prematur ovulering

Country Status (16)

Country Link
US (1) US20090048273A1 (no)
EP (1) EP1917978B1 (no)
JP (1) JPWO2007011072A1 (no)
KR (1) KR20080041662A (no)
CN (1) CN101272806A (no)
AU (1) AU2006270749B2 (no)
BR (1) BRPI0613643A2 (no)
CA (1) CA2615795C (no)
ES (1) ES2494842T3 (no)
IL (1) IL188764A (no)
MX (1) MX2008000820A (no)
NO (1) NO339063B1 (no)
NZ (1) NZ566038A (no)
RU (1) RU2419435C2 (no)
WO (1) WO2007011072A1 (no)
ZA (1) ZA200801150B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008094846A (ja) * 2003-01-29 2008-04-24 Takeda Chem Ind Ltd チエノピリミジン化合物およびその用途
EP1998976B1 (en) 2006-03-15 2012-01-18 TM4 Inc. Hybrid transmission for hybrid vehicles
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
CN105732649B (zh) * 2012-02-28 2019-02-05 株式会社蒂奥姆生物 促性腺激素释放激素受体拮抗剂、其制备方法和包含该拮抗剂的药物组合物
ES2724206T3 (es) * 2012-09-28 2019-09-09 Takeda Pharmaceuticals Co Método de producción de un derivado de tienopirimidina
IL300580A (en) 2016-09-30 2023-04-01 Takeda Pharmaceuticals Co Methods for treating uterine fibroids and endometrial disease
MX2019003733A (es) 2016-09-30 2019-09-26 Myovant Sciences Gmbh Tratamiento de cancer de prostata.
CN109490530A (zh) * 2018-11-21 2019-03-19 长沙金域医学检验所有限公司 一种抗精子抗体检测方法
WO2021018105A1 (en) * 2019-07-29 2021-02-04 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
CN111574534B (zh) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
CN113754679B (zh) * 2020-09-09 2023-04-07 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
WO2022067573A1 (zh) * 2020-09-29 2022-04-07 广东东阳光药业有限公司 磺酰胺基取代的杂芳基嘧啶二酮类化合物及其用途
CN116411028A (zh) * 2023-01-06 2023-07-11 西南大学 桔小实蝇嗅觉受体OR43a-1和OR63a-2的应用及其突变体的构建方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003505A2 (en) 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
US8173592B1 (en) * 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
US7569570B2 (en) * 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
AU2004207706B2 (en) * 2003-01-29 2010-03-04 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
JP4039574B2 (ja) * 2003-01-29 2008-01-30 武田薬品工業株式会社 チエノピリミジン化合物およびその用途
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof

Also Published As

Publication number Publication date
EP1917978B1 (en) 2014-08-20
RU2419435C2 (ru) 2011-05-27
ES2494842T3 (es) 2014-09-16
ZA200801150B (en) 2010-05-26
KR20080041662A (ko) 2008-05-13
AU2006270749B2 (en) 2013-02-07
IL188764A0 (en) 2008-08-07
WO2007011072A1 (ja) 2007-01-25
US20090048273A1 (en) 2009-02-19
CA2615795A1 (en) 2007-01-25
JPWO2007011072A1 (ja) 2009-02-05
CA2615795C (en) 2013-05-28
NZ566038A (en) 2011-06-30
CN101272806A (zh) 2008-09-24
NO339063B1 (no) 2016-11-07
EP1917978A4 (en) 2010-10-06
BRPI0613643A2 (pt) 2012-11-06
AU2006270749A1 (en) 2007-01-25
RU2008106754A (ru) 2009-08-27
EP1917978A1 (en) 2008-05-07
MX2008000820A (es) 2008-03-18
IL188764A (en) 2014-11-30

Similar Documents

Publication Publication Date Title
NO20080869L (no) For tidlig egglosningspreventivt middel
WO2020016659A3 (en) Multiparticulate formulations of cannabinoids
NO20074412L (no) Bruddresistente administrasjonsformer med forsinket frigiving
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
NO20073802L (no) Leuprolidacetat og acetylkolinsteraseinhibitor eller NMDA-reseptorantagonister for behandlingen av Alzheimers sykdom
AR050616A1 (es) Composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos.
EP1993567A4 (en) PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CL2009001936A1 (es) Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006).
BRPI0709057B8 (pt) veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação
MX2009004858A (es) Forma de dosificacion de imatinib procesada en fusion.
DK1906916T3 (da) Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
DK2219665T3 (da) Parathyroidhormonformuleringer og anvendelse deraf
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
UY29109A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
ITGE20040036A1 (it) Fibbia di tensionamento dei cinghioli delle pinne o simili,provvista di mezzi di agganciamento e sgaciamento rapido e facilitato.
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
AR056067A1 (es) Procedimiento para la proteccion contra fitopatogenos mediante quiralaxil, uso correspondiente y agentes destinados a ese fin
TW200715513A (en) Contacts to microdevices
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
EP2138172A8 (en) Anti-viral agent
UY28630A1 (es) Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol
MX2022007988A (es) Formas cristalinas de (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения